Fakultni Thomayerova nemocnice

Prague 14059

9 studies enrolling now · 23 studies all time

What they study most

Advanced Non-Small Cell Lung Cancer, Atherosclerotic Cardiovascular Disease (ASCVD), Breast Cancer, Breast Neoplasms, Cancer of the Prostate, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Carcinoma, Transitional Cell, Chronic Kidney Disease (CKD), Chronic Migraine, Colitis, Ulcerative

Studies at this site

• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer — Recruiting now
• A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema — Recruiting now
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer — Recruiting now
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Recruiting now
• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract — Recruiting now
• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer — Recruiting now
• Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis — Stopped early
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. — Stopped early
• A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults — Running, not enrolling
• A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults — Running, not enrolling
• A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation — Completed
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
• A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) — Running, not enrolling
• Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression — Completed
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed
• Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN — Withdrawn before enrolling
• Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo — Completed
• E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer — Completed